Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: TNFerade, GenVec.

Ralf Kircheis1, Ernst Wagner

  • 1Igeneon Immunotherapy of Cancer, Brunner Strasse 69/3, A-1230 Vienna, Austria. ralf.kircheis@igeneon.com

Current Opinion in Molecular Therapeutics
|September 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Silico Modeling of Structural Compatibility and Alignment Between Viral Class I Fusion Cores and Human TLR4/MD-2.

International journal of molecular sciences·2026
Same author

Poly(I:C) Lipoamino Bundle LNPs Induce Tumor Cytotoxicity and Immune Activation with Enhanced Efficacy by Survivin Silencing.

International journal of molecular sciences·2026
Same author

mRNA Delivery by Lipoamino Fatty Acid-Peptide Polyplexes in Different Lung Cell Models and Lungs.

Polymers·2026
Same author

Spatiotemporal Nanotransformers for Antitumoral Orchestration of Protein Homeostasis.

Polymer science & technology (Washington, D.C.)·2026
Same author

Enhanced Intramuscular mRNA Activity of Peptide-Lipid Nanoparticles with Hydrophobized Head Groups.

Bioconjugate chemistry·2026
Same author

Development of CAR NK Cell Lines Selectively Targeting Cancer Cells Expressing Membrane Hsp70.

MedComm·2026
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

GenVec

Area of Science:

  • Oncology
  • Gene Therapy
  • Molecular Biology

Background:

  • Cancer treatment remains a significant challenge.
  • Tumor necrosis factor (TNF)-alpha is a key cytokine involved in inflammation and cell death.
  • Gene therapy offers a novel approach to targeted cancer treatment.

Purpose of the Study:

  • To evaluate TNFerade, a novel gene therapy for cancer.
  • To assess the potential of radiation-sensitive promoters in cancer treatment.

Main Methods:

  • Development of a replication-deficient adenovector carrying the human TNF-alpha gene.
  • Utilizing a radiation-sensitive promoter for targeted gene expression.
  • Phase II clinical trials for cancer treatment.

Related Experiment Videos

Main Results:

  • TNFerade is under investigation for its therapeutic potential in cancer.
  • The drug employs a targeted delivery system for TNF-alpha.
  • Phase II trials are ongoing to assess efficacy and safety.

Conclusions:

  • TNFerade represents a promising gene therapy candidate for cancer.
  • The use of radiation-sensitive promoters allows for targeted therapeutic effects.
  • Further clinical evaluation is necessary to establish its role in oncology.